Mather Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
VPM
VCM
Mather Group's NBIX Position: Q1 2026 in Review
Mather Group opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 158 shares worth $20.8K. The stake represents ﹤0.01% of the portfolio and ranks #1267 among its holdings. This is a return to the name: Mather Group previously reported a position in NBIX as recently as Q3 2025.
Mather Group first reported a position in NBIX in Q1 2024 and has held it in 7 quarters since. The position peaked at $31.9K in Q2 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Mather Group held 158 shares of Neurocrine Biosciences worth $20.8K as of Q1 2026.
- Neurocrine Biosciences was a new Mather Group position in Q1 2026.
- Neurocrine Biosciences made up ﹤0.01% of Mather Group's portfolio in Q1 2026, its #1267 holding.
- Mather Group first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 7 quarters since.
- Mather Group's Neurocrine Biosciences position peaked at $31.9K in Q2 2024.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Mather Group's 13F filing for Q1 2026, filed 13 Apr 2026.